6-姜酚对心肾综合征大鼠心肾功能的影响

doi:10.3969/j.issn.1006-5725.2025.11.004

Abstract

Abstract:

Objective To evaluate whether 6-gingerol（6G）can inhibit fibrosis and improve the cardiac and renal function and in rats with cardiorenal syndrome. Methods In the in vitro experiments of this study， the incorporation of isotope-labeled amino acids was used to detect the intervention of 6-gingerol on normal rat kidney-49F （NRK-49F） and normal rat kidney-52E （NRK-52E） cells. 68 male SD rats weighing 200 ~ 250 g were used to establish a rat model of cardiorenal syndrome by ligating the left anterior descending coronary artery and performing 5/6 nephrectomy. The rats were randomly divided into a control group， a model group， a low dose 6-gingerol group （6 mg/kg）， a high dose 6-gingerol group （30 mg/kg）， and a losartan potassium group （20 mg/kg）. The 6-gingerol group received intraperitoneal injection of 6-gingerol， while the control group and model group received intraperitoneal injection of an equal amount of physiological saline. The losartan group received oral administration of losartan potassium for a total of 6 weeks. After successful modeling， blood samples were taken for biochemical and cardiac ultrasound examinations. After the experiment， blood， heart， and kidney samples were taken for Masson， immunohistochemistry， and Western blot. Results 6-gingerol 20 μmol/L can reduce NRK-49F collagen synthesis and inhibit NRK-52E protein synthesis. Biochemical results showed that the serum creatinine， urea nitrogen， and brain natriuretic peptide （BNP） levels of rats in the low and high dose 6-gingerol groups and the losartan group were all reduced， with high dose 6-gingerol groups and losartan group showing the most significant decrease （P < 0.05）. Echocardiographic parameters showed that the 6-gingerol group and losartan potassium group improved cardiac contractile function and ventricular remodeling in rats （P < 0.05）. Masson staining and Western Blot showed renal collagen deposition， with reduced expression of collagen I and α-SMA （P < 0.05）. Immunofluorescence showed a decrease in the expression of renal collagen deposition I， α-SMA， and TGF-β1 （P < 0.05）. Conclusion 6-Gingerol may improve the cardiac and renal function and renal fibrosis in rats with cardiorenal syndrome.

Key words: 6?gingerol, cardiorenal syndrome, fibrosis, cardiac function, renal function

CLC Number:

R541.6+1

Ting DENG,Qiang FU,Zhiliang LI,Qingmin CHU,Xiaoxiong. ZHOU. Study on the improvement of cardiac and renal function in rats with cardiorenal syndrome by inhibiting fibrosis with 6-gingerol[J]. The Journal of Practical Medicine, 2025, 41(11): 1627-1636.

Figures/Tables 10

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

Fig.6

Fig.7

Fig.8

Fig.9

Fig.10

References 32

1	RICCI Z， ROMAGNOLI S， RONCO C. Cardiorenal Syndrome［J］. Crit Care Clin， 2021， 37（2）：335-347. doi:10.1016/j.ccc.2020.11.003 doi: 10.1016/j.ccc.2020.11.003
2	SHAAYA G， AL-KHAZAALI A， ARORA R. Heart Rate As a Biomarker in Heart Failure： Role of Heart Rate Lowering Agents［J］. Am J Ther， 2017， 24（5）：e532-e539. doi:10.1097/mjt.0000000000000336 doi: 10.1097/mjt.0000000000000336
3	SZLAGOR M， DYBIEC J， MLYNARSKA E， et al. Chronic Kidney Disease as a Comorbidity in Heart Failure［J］. Int J Mol Sci， 2023， 24（3）：2988. doi:10.3390/ijms24032988 doi: 10.3390/ijms24032988
4	CARMENA R， ASCASO J F， REDON J. Chronic kidney disease as a cardiovascular risk factor［J］. J Hypertens， 2020， 38（11）：2110-2121. doi:10.1097/hjh.0000000000002506 doi: 10.1097/hjh.0000000000002506
5	TWARDAWA M， FORMANOWICZ P， FORMANOWICZ D. Chronic Kidney Disease as a Cardiovascular Disorder-Tonometry Data Analyses［J］. Int J Environ Res Public Health， 2022， 19（19）：12339. doi:10.3390/ijerph191912339 doi: 10.3390/ijerph191912339
6	PRICE A M， EDWARDS N C， HAYER M K， et al. Chronic kidney disease as a cardiovascular risk factor： Lessons from kidney donors［J］. J Am Soc Hypertens， 2018， 12（7）：497-505. doi:10.1016/j.jash.2018.04.010 doi: 10.1016/j.jash.2018.04.010
7	OTAKI Y， WATANABE T， TAKAHASHI H， et al. Association of renal tubular damage with cardio-renal anemia syndrome in patients with heart failure［J］. Int J Cardiol， 2014， 173（2）：222-228. doi:10.1016/j.ijcard.2014.02.044 doi: 10.1016/j.ijcard.2014.02.044
8	LI W， ZHANG Y， WANG Q， et al. 6-Gingerol ameliorates ulcerative colitis by inhibiting ferroptosis based on the integrative analysis of plasma metabolomics and network pharmacology［J］. Food Funct， 2024， 15（11）：6054-6067. doi:10.1039/d4fo00952e doi: 10.1039/d4fo00952e
9	HAN X， LIU P， LIU M， et al. ［6］-Gingerol Ameliorates ISO-Induced Myocardial Fibrosis by Reducing Oxidative Stress， Inflammation， and Apoptosis through Inhibition of TLR4/MAPKs/NF-kappaB Pathway［J］. Mol Nutr Food Res， 2020， 64（13）：e2000003. doi:10.1002/mnfr.202000003 doi: 10.1002/mnfr.202000003
10	YAHYAZADEH R， BARADARAN R V， AHMAD M S， et al. Intra-peritoneal lavage of Zingiber officinale rhizome and its active constituent gingerol impede inflammation， angiogenesis， and fibrosis following post-operative peritoneal adhesion in male rats［J］. Saudi Pharm J， 2024， 32（6）：102092. doi:10.1016/j.jsps.2024.102092 doi: 10.1016/j.jsps.2024.102092
11	石晓路，武乾. 去甲乌药碱与6-姜酚配伍对心衰大鼠强心机制研究［J］. 中华中医药杂志， 2016， 31（2）：420-423.
12	LIU L， YU N， LENG W， et al. 6-Gingerol， a functional polyphenol of ginger， reduces pulmonary fibrosis by activating Sirtuin1［J］. Allergol Immunopathol （Madr），2022，50（2）：104-114. doi:10.15586/aei.v50i2.533 doi: 10.15586/aei.v50i2.533
13	ALGANDABY M M， EL-HALAWANY A M， ABDALLAH H M， et al. Gingerol protects against experimental liver fibrosis in rats via suppression of pro-inflammatory and profibrogenic mediators［J］. Naunyn Schmiedebergs Arch Pharmacol， 2016， 389（4）：419-428. doi:10.1007/s00210-016-1210-1 doi: 10.1007/s00210-016-1210-1
14	MA S Q， GUO Z， LIU F Y， et al. 6-Gingerol protects against cardiac remodeling by inhibiting the p38 mitogen-activated protein kinase pathway［J］. Acta Pharmacol Sin， 2021， 42（10）：1575-1586. doi:10.1038/s41401-020-00587-z doi: 10.1038/s41401-020-00587-z
15	SONG Z， FANG H， ZHANG X， et al. Renoprotective Glycoside Derivatives from Zingiber officinale （Ginger） Peels［J］. J Agric Food Chem， 2023， 71（41）：15170-15185. doi:10.1021/acs.jafc.3c05224 doi: 10.1021/acs.jafc.3c05224
16	SHEN Z， SU T， CHEN J， et al. Collagen triple helix repeat containing-1 exerts antifibrotic effects on human skin fibroblast and bleomycin-induced dermal fibrosis models［J］. Ann Transl Med， 2021， 9（9）：801. doi:10.21037/atm-21-1884 doi: 10.21037/atm-21-1884
17	SHEN Z， SU T， CHEN J， et al. Collagen triple helix repeat containing-1 exerts antifibrotic effects on human skin fibroblast and bleomycin-induced dermal fibrosis models［J］. Ann Transl Med， 2021， 9（9）：801. doi:10.21037/atm-21-1884 doi: 10.21037/atm-21-1884
18	ZHANG Y F， WANG Q， LUO J， et al. Knockdown of elF3a inhibits collagen synthesis in renal fibroblasts via Inhibition of transforming growth factor-beta1/Smad signaling pathway［J］. Int J Clin Exp Pathol， 2015， 8（8）：8983-8989.
19	LIU S， KOMPA A R， KUMFU S， et al. Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction： implications for cardiorenal syndrome［J］. Int J Cardiol， 2013， 168（3）：1866-1880. doi:10.1016/j.ijcard.2012.12.065 doi: 10.1016/j.ijcard.2012.12.065
20	ZHAO R R， ACKERS-JOHNSON M， STENZIG J， et al. Targeting Chondroitin Sulfate Glycosaminoglycans to Treat Cardiac Fibrosis in Pathological Remodeling［J］. Circulation， 2018， 137（23）：2497-2513. doi:10.1161/circulationaha.117.030353 doi: 10.1161/circulationaha.117.030353
21	YANG K， WANG C， NIE L， et al. Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy［J］. J Am Soc Nephrol， 2015， 26（10）：2434-2446. doi:10.1681/asn.2014060543 doi: 10.1681/asn.2014060543
22	LIU H， ZHU R， LIU C， et al. Evaluation of Decalcification Techniques for Rat Femurs Using HE and Immunohistochemical Staining［J］. Biomed Res Int， 2017， 2017：9050754. doi:10.1155/2017/9050754 doi: 10.1155/2017/9050754
23	IRIE N， LEE S M， LORENZI V， et al. DMRT1 regulates human germline commitment［J］. Nat Cell Biol， 2023， 25（10）：1439-1452. doi:10.1038/s41556-023-01224-7 doi: 10.1038/s41556-023-01224-7
24	GHOSH-CHOUDHARY S， FINKEL T. Lactylation regulates cardiac function［J］. Cell Res， 2023， 33（9）：653-654. doi:10.1038/s41422-023-00857-5 doi: 10.1038/s41422-023-00857-5
25	SU S A， YANG D， WU Y， et al. EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-beta/Smad3 Signaling［J］. Circ Res， 2017， 121（6）：617-627. doi:10.1161/circresaha.117.311045 doi: 10.1161/circresaha.117.311045
26	ZANNAD F， ROSSIGNOL P. Cardiorenal Syndrome Revisited［J］. Circulation， 2018， 138（9）：929-944. doi:10.1161/circulationaha.117.028814 doi: 10.1161/circulationaha.117.028814
27	DELGADO-VALERO B， CACHOFEIRO V， MARTINEZ-MARTINEZ E. Fibrosis， the Bad Actor in Cardiorenal Syndromes： Mechanisms Involved［J］. Cells， 2021， 10（7）：1824. doi:10.3390/cells10071824 doi: 10.3390/cells10071824
28	XU X， ZHANG B， WANG Y， et al. Renal fibrosis in type 2 cardiorenal syndrome： An update on mechanisms and therapeutic opportunities［J］. Biomed Pharmacother， 2023， 164：114901. doi:10.1016/j.biopha.2023.114901 doi: 10.1016/j.biopha.2023.114901
29	曹浩，吉霆威，兰琴，等. 经腹肾次全切建立大鼠心肾综合征模型［J］. 中华医学杂志， 2019， 99（6）：447-452. doi:10.3760/cma.j.issn.0376-2491.2019.06.013 doi: 10.3760/cma.j.issn.0376-2491.2019.06.013
30	DENG T， WEI Z， GAEL A， et al. Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway［J］. J Cardiovasc Pharmacol， 2020， 75（6）：535-544. doi:10.1097/fjc.0000000000000822 doi: 10.1097/fjc.0000000000000822
31	QIU Q， CAO J， WANG Y， et al. Time Course of the Effects of Buxin Yishen Decoction in Promoting Heart Function and Inhibiting the Progression of Renal Fibrosis in Myocardial Infarction Caused Type 2 Cardiorenal Syndrome Rats［J］. Front Pharmacol， 2019， 10：1267. doi:10.3389/fphar.2019.01267 doi: 10.3389/fphar.2019.01267
32	ZHAO Y， WANG C， HONG X， et al. Wnt/beta-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome［J］. Kidney Int， 2019， 95（4）：815-829. doi:10.1016/j.kint.2018.11.021 doi: 10.1016/j.kint.2018.11.021

[1]	Hanjie ZENG,Min HUANG,Qian ZHANG,Dongmei ZHU,Suming. ZHOU. The precision and accuracy of five equations for estimated glomerular filtration rate in evaluating renal function in critically ill patients [J]. The Journal of Practical Medicine, 2025, 41(8): 1243-1252.
[2]	Yue LV,Yanna MENG,Panpan LI,Yinghong. CHEN. Value of SWD in preoperative assessment of liver fibrosis in patients with hepatocellular carcinoma [J]. The Journal of Practical Medicine, 2025, 41(5): 751-755.
[3]	Xin ZHAO,Hui LI,Xiuxiu DENG,Yujing. TAO. Antiplatelet drugs and liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(8): 1083-1087.
[4]	Renling YAO,Yixuan ZHU,Rui HUANG,Jie LI. The association between vitamin intake and the progression of metabolic dysfunction⁃associated fatty liver disease [J]. The Journal of Practical Medicine, 2024, 40(6): 820-826.
[5]	Juan TANG,Yi LI,Liqiong ZHAI,Shaowen LIU,Yong SHEN,Shuo CONG,Yongmei. LIU. The diagnostic value of miR⁃571 levels in blood from the peripherals in liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(5): 653-657.
[6]	Ningjing SONG,Jing ZHOU,Biwei CAO,Yan ZHAO,Yunyang YU,Hanli LEI,Yujun. LUO. TGF⁃β′s role in skeletal muscle injury repair： Mechanism and research advances [J]. The Journal of Practical Medicine, 2024, 40(5): 721-726.
[7]	Aiqin LI,Zhen ZHANG,Ya′nan XU,Jinyuan ZHU,Xu. ZHANG. Research progress on the interaction between macro⁃phages and fibroblasts in ARDS pulmonary fibrosis [J]. The Journal of Practical Medicine, 2024, 40(4): 571-574.
[8]	Jinhui XU,Mailong YUAN,Tao ZHOU,Mingsheng ZHANG,Yaqi. LI. Effects of sevoflurane or propofol anesthesia maintenance on renal function and postoperative cognition in patients undergoing liver transplantation [J]. The Journal of Practical Medicine, 2024, 40(24): 3509-3514.
[9]	Lixiu LIU,Guofeng LI,Honglan ZHONG,Huaying HUANG,Xiuzhen WEN,Xiang. LI. Effect of tiopronin on renal function during antituberculosis therapy [J]. The Journal of Practical Medicine, 2024, 40(23): 3362-3366.
[10]	Yingyuan ZHANG,Chunyan MOU,Danqing XU,Yuanzhen WANG,Lixian CHANG,Chunyun LIU,Weikun LI,Hongyan WEI,Li LIU. Comparison of clinical efficacy of TMF and TDF in the treatment of hepatitis B liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(22): 3215-3220.
[11]	Jia XIANG,Qiantong CHEN,Yingxin LU,Sijie ZHENG,Junjie HUANG,Yingying CHEN,Suidan HUANG,Huai. CHEN. Study on diffuse cystic lung disease based on deep learning [J]. The Journal of Practical Medicine, 2024, 40(19): 2747-2754.
[12]	Yihuan CHEN,Zhenya SHEN,Yunsheng YU,Haoyue HUANG,Wenxue YE,Fei HUA,Yanqiu. HU. Observation on the effects and complications of mitral valve membrane replacement surgery with preservation of mitral valve subvalvular structure on cardiac function and valve function [J]. The Journal of Practical Medicine, 2024, 40(15): 2092-2097.
[13]	Xiaojing CAI,Yonglian HUANG,Fei ZHOU,Xianwen. TANG. Clinical observation of umbilical moxibustion in treating chronic heart failure with Yang deficiency syndrome of blood stasis and water withdrawal [J]. The Journal of Practical Medicine, 2024, 40(14): 2021-2026.
[14]	Jingwen AN,Junyun FENG,Lei RAO,Dewu LIU. Research progress on relationship between cellular senescence and scar fibrosis [J]. The Journal of Practical Medicine, 2024, 40(12): 1749-1754.
[15]	Jin LU,Ming WEN,Qingrong TANG,Chunhua XU,Chunling ZHAN,Yizhou XU,Lihui. YANG. The relationship between the expression of serum GP3 and CHI3L1 and the degree of liver fibrosis and pathological changes in patients with hepatitis [J]. The Journal of Practical Medicine, 2024, 40(11): 1586-1591.

Study on the improvement of cardiac and renal function in rats with cardiorenal syndrome by inhibiting fibrosis with 6-gingerol

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 32

Related Articles 15

Recommended Articles

Metrics

Comments